MPS Q3 FY26 results, Unbound Medicine buy, director exit
MPSLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.9 pts less than Nifty Microcap 250 and 6.7 pts less than its Printing & Publication peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
MPS Limited posted Q3 and 9M FY26 results. Consolidated quarterly revenue about Rs 72.7 cr and PBT Rs 16.4 cr. Standalone 9M revenue dipped roughly 6 percent to Rs 351 cr. Booked exceptional items: Rs 6.11 cr Labour Codes impact standalone and Rs 15.73 cr write-back from MPSi subsidiary restructuring. Subsidiary MPS North America LLC will acquire US-based Unbound Medicine for USD 16.5 million. Non-Executive Director Yamini Tandon resigned for personal reasons. Auditor Walker Chandiok issued an unmodified limited review.
Standalone revenue softness offset by strong consolidated profits and a new US acquisition. Director exit is a routine governance change.